EirGenix
Zhubei City, Hsinchu County, Taiwan
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (6)
○ EMA GMP
○ MHRA GMP
Quick Facts: EirGenix
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Zhubei City, Hsinchu County, Taiwan
- Modalities
- Monoclonal Antibody, Bispecific/Polyclonal Antibody, Recombinant Protein, ADC, Biosimilars, Plasmid DNA
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About EirGenix
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Bispecific/Polyclonal Antibody, Recombinant Protein, ADC, Biosimilars, Plasmid DNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (6 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press6 articles
Broad modality coverage (6 modalities)
Recent News 6 articles
Eirgenix Protein Drug Production Plant, Zhubei, Taiwan - Pharmaceutical Technology
EirGenix Advances into CPHI Japan, Capitalizing on Market Trends to Deepen Its Strategic Footprint in Japan - PR Newswire
EirGenix Leverages Dual Engines of CDMO and Biosimilars to Capitalize on Global Biopharma Supply Chain Realignment - geneonline.com
EirGenix Licenses Transcenta’s HiCB Platform to Improve Process Efficiency - Contract Pharma
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng - geneonline.com
Transcenta Inks Licensing Deal with EirGenix to Advance Continuous Biomanufacturing - Genetic Engineering and Biotechnology News
Frequently Asked Questions About EirGenix
What is EirGenix's CDMO Signal Score?
EirGenix has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating EirGenix for a manufacturing program?
Use the free AI matchmaker to compare EirGenix against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
Signal Score: 76.5
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
Signal Score: 75.1
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 83.5
Monoclonal Antibody, Recombinant Protein, AAV, Plasmid DNA
Samsung Biologics
Incheon, South Korea
Signal Score: 68.5
Monoclonal Antibody, Recombinant Protein, ADC, mRNA
Bionova Scientific
Fremont, CA
Signal Score: 59.0
Monoclonal Antibody, Recombinant Protein, Plasmid DNA